Baxalta Inc (BXLT) Files Form 4 Insider Buying : Blake E Devitt Buys 387 Shares

Baxalta Inc (BXLT): Blake E Devitt , director of Baxalta Inc purchased 387 shares on May 24, 2016. The Insider buying transaction was reported by the company on May 26, 2016 to the Securities and Exchange Commission. The shares were purchased at $0.00 per share for a total value of $0.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 28, 2016, James R Iii Gavin (director) sold 5,660 shares at $39.97 per share price.On Mar 28, 2016, John D Forsyth (director) sold 5,660 shares at $39.97 per share price.Also, On Mar 28, 2016, Albert P L Stroucken (director) sold 5,660 shares at $39.98 per share price.

Baxalta Inc: On Wednesday, May 25, 2016 heightened volatility was witnessed in Baxalta Inc which led to swings in the share price. The shares opened for trading at $45.48 and hit $45.71 on the upside , eventually ending the session at $45.71, with a gain of 1.58% or 0.71 points. The heightened volatility saw the trading volume jump to 1,26,92,805 shares. The 52-week high of the share price is $45.28 and the company has a market cap of $31,245 M . The 52-week low of the share price is at $29.8295.

Baxalta Inc Money Flow Index Chart

On May 10, 2016, Baxalta Inc announced a cash dividend of $0.0700. The company’s management has announced Jun 8, 2016 as the ex-dividend date and fixed the record date on Jun 10, 2016. The payable date has been fixed on Jul 1, 2016.

Baxalta Incorporated is a biopharmaceutical company. The Company develops manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute medical conditions. The Company also focuses on disease areas including oncology as well as technology platforms including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas including hemophilia immunology and oncology. The Company’s products include ADVATE RECOMBINATE HEMOFIL M Immunate Immunine PROTHROMPLEX TOTAL RIXUBIS FACTOR VII NF BEBULIN FEIBA OBIZUR GAMMAGARD LIQUID GAMMAGARD S/D Subcuvia HYQVIA FLEXBUMIN BUMINATE ARALAST NP GLASSIA NP CEPROTIN and ANTITHROMBIN III IMMUNO.

Leave a Reply

Baxalta Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Baxalta Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.